Canada: BC Court Of Appeal Dismisses Proposed Consumer Class Action For Invalid Pharmaceutical Patent

Last Updated: December 17 2015
Article by Kiernan A. Murphy

On Dec. 8, 2015, the British Columbia Court of Appeal dismissed a proposed class action by consumers against Pfizer Canada Inc. in connection with Pfizer's now invalid patent which covered its VIAGRA® product.1 The Court of Appeal overturned the lower court's finding that the plaintiff's claim disclosed a cause of action, one of the threshold requirements for certifying a class action. Britton Low, the proposed representative plaintiff, alleged that Pfizer unlawfully abused the patent system, and as a result, was able to overcharge purchasers of VIAGRA. The lower court found that it was plain and obvious that Mr. Low's claim in waiver of tort could not succeed, but allowed his claims for interference with economic relations and unjust enrichment to go forward. However, in a unanimous decision, the Court of Appeal found that those claims also could not succeed.

In particular, the Court of Appeal held that the Patent Regulatory Regime2 constitutes a complete code. Even though this regime includes no remedy for consumers for conduct alleged to have breached that regime, the Court held that:

...the completeness of the Patent Regulatory Regime forecloses parallel civil actions by consumers that are rooted in a breach of the Patent Act... [T]here is nothing in the legislation comprising the Patent Regulatory Regime ... that evinces an intention to allow consumers to make such claims.


Pfizer obtained a patent on the use of several compounds, including sildenafil (the medicinal ingredient in VIAGRA), in the treatment of erectile dysfunction. In 2006, a generic manufacturer sought regulatory approval to market a copycat version of VIAGRA, and was thus required to address that patent pursuant to the Patented Medicines (Notice of Compliance) Regulations (the "NOC Regulations"). The generic asserted that Pfizer's patent was invalid. Pfizer commenced a prohibition proceeding under those regulations, triggering an automatic stay of that generic's regulatory approval. The Federal Court granted prohibition, finding the generic's allegations to be unjustified, and the Court of Appeal upheld that order. However, the Supreme Court of Canada then found one of the allegations of invalidity to be justified and dismissed the prohibition application, allowing the generic to enter the market.

Patent Regulatory Regime is a Complete Code

The Court of Appeal held that several decisions of the Federal Court of Appeal support the notion that the Patent Regulatory Regime is a complete code as between brands and generics. For example, it highlighted a decision finding a claim by a generic manufacturer beyond the Patent Regulatory Regime could not possibly succeed because the allegedly wrongful acts were the same as those underlying liability under that regime.3 The Court of Appeal also referred to the Ontario Court of Appeal's finding4 that the Patent Regulatory Regime does not leave room for any stand-alone equitable remedies.

The Court of Appeal noted that comprehensive statutory schemes may preclude common law rights, including unjust enrichment. It clarified that the Patent Regulatory Regime does not confer any direct benefit or protection on consumers and thus the absence of an enforcement mechanism in this regime cannot imply a common law private cause of action by a consumer.

As quoted above, the Court of Appeal concluded that nothing in the Patent Regulatory Regime conveys an intention to permit parallel civil actions by consumers that are rooted in a breach of the Patent Act. Indeed, it noted that it would make no sense to allow consumers to claim disgorgement of profits from brands when generics are precluded from doing the same based on identical allegedly wrongful acts.

In any event, the Court of Appeal noted that there was evidence that Parliament had in fact considered consumer interests and chose to create, for example, the Patented Medicines Prices Review Board to reduce prices deemed excessive.

No Cause of Action for Unjust Enrichment or Interference with Economic Relations

The Court of Appeal also held that Pfizer could not be liable for conduct grounding Mr. Low's claim for interference with economic relations because it has no corresponding liability to generics (outside of the NOC Regulations) for the same conduct. This tort creates a "parasitic" liability as it requires a distinct unlawful act (or actionable civil wrong of some kind). A breach of statute (such as the Patent Act) must therefore be actionable outside the context of the statute itself. Mr. Low had alleged that Pfizer's acts were actionable by third party generic drug manufacturers who were kept off the market. The Court of Appeal however noted that generics could only claim their own losses pursuant to the NOC Regulations. As such, it held that, if generics have no cause of action against brands beyond those regulations, then the entirely parasitic tort of unlawful interference with economic relations could not succeed.

The Court of Appeal confirmed that complete statutory codes, such as the Patent Regulatory Regime, exclude equitable claims in unjust enrichment and thus Mr. Low had no claim in this regard. It added that the lower court ought to have found that this claim had no prospect of success in any event, having held that Pfizer's contracts with its direct purchasers (e.g., distributors or pharmacies) constituted a juristic reason for any benefits obtained by Pfizer. The Court of Appeal held that a single juristic reason is enough to defeat an unjust enrichment claim.


The Court of Appeal's finding that none of the proposed claims met the very low threshold for establishing that the proposed class action discloses a cause of action during the certification process should provide some comfort to brands seeking to exercise patent rights which could subsequently be found invalid. In addition, its conclusion in the context of consumer claims that the Patent Regulatory Regime is a complete code clarifies the scope of, and available rights under, that regime. That finding, in line with recent jurisprudence involving generics, further confines the redress generics may seek for being kept off the market by application of the NOC Regulations to that expressly set out in those regulations.


1. Low v Pfizer Canada Inc.,2015 BCCA 506

2. The Court of Appeal referred collectively to the Patent Act, R.S.C. 1985, c. P-4, the Food and Drugs Act, R.S.C. 1985, c. F-27, the Food and Drug Regulations, C.R.C., c. 870, Part C, Division 8, C.08.004, and the Patented Medicines (Notice of Compliance) Regulations, S.O.R./93-133 as the "Patent Regulatory Regime".

3. Apotex v Eli Lilly, 2011 FCA 358

4. Apotex Inc v Abbot Laboratories Ltd, 2013 ONSC 356, aff'd 2013 ONCA 555

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.